drugset / Trial / NCT01538472

Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma

NCT01538472

Phase 1/2 Completed 40 enrolled M.D. Anderson Cancer Center Biogen · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to see if high-dose chemotherapy (BEAM) and rituximab, given together with the new drug 90Y Zevalin, followed by a transplant of blood or marrow stem cells is safe. Another goal is to learn if this treatment can help decrease the chances of the cancer coming back.

Timeline

Start
2003-09
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject In Zevalin Unknown 5 mbq Intravenous
Subject Y Zevalin Protein / enzyme biologic 0.4 mbq/kg Intravenous
Background Cytarabine Small molecule 200 mg/m2 Intravenous
Background Etoposide Small molecule 200 mg/m2 Intravenous
Background G-CSF Unknown 5 mg/kg Intravenous
Background Melphalan Small molecule 140 mg/m2 Intravenous
Background Rituximab Monoclonal antibody 1000 mg/m2 Intravenous
Background carmustine Small molecule 300 mg/m2 Intravenous

Indications